Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Phase 3

Completed

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: Teneligliptin/Canagliflozin

• Registration Number: NCT02220907
• Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2014-08-19
• Study First Submitted QC: 2014-08-19
• Study First Posted: 2014-08-20
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Results First Submitted: 2017-11-16
• Results First Submitted QC: 2017-11-16
• Results First Posted: 2018-08-16
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-03
• Last Update Posted: 2018-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 153

Inclusion Criteria

• Men or women age ≥20 years old
• HbA1c of ≥7.0% and <10.5%
• FPG of ≤ 270 mg/dL
• Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before treatment period

Read More

Exclusion Criteria

• Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes
• Patients with serious diabetic complications
• Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria
• Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification
• Patients with severe hepatic disorder or severe renal disorder.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Teneligliptin/Canagliflozin	Teneligliptin/Canagliflozin	Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events	52 Weeks

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)	Baseline, 52 Weeks	The change from baseline in percentage of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 52.
Change From Baseline in Fasting Plasma Glucose Level	Baseline, 52 Weeks	The change from baseline in fasting plasma glucose level collected at Week 52.
Percentage Change in Body Weight From Baseline	Baseline, 52 Weeks	The percentage change from baseline in body weight collected at Week 52.

Trial Locations

Locations (1)

Research site; 🇯🇵 Tohoku, Japan